ImageneBio, Inc. (NASDAQ: IMA)

ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company's lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody designed to bind the OX40 receptor on activated T cells and block its interaction with OX40 ligand. IMG-007 is being evaluated for multiple indications, beginning with atopic dermatitis, with potential expansion into conditions such as alopecia areata, asthma, rheumatoid arthritis, and hidradenitis suppurativa.

ImageneBio, Inc. generates revenue through the potential future commercialization of its therapeutic candidates, primarily IMG-007, which is intended for the treatment of autoimmune and inflammatory diseases. The company does not currently generate product revenue as its candidates remain in clinical development. Revenue will be derived from sales of approved therapeutics, licensing agreements, and potential collaborations once clinical milestones are achieved and regulatory approvals are obtained.

ImageneBio, Inc. operates through a single segment focused on the research, development, and commercialization of biologic therapeutics for immunological and inflammatory conditions.

• Research and Development: This segment encompasses the discovery, preclinical testing, and clinical evaluation of IMG-007 and other potential candidates targeting the OX40-OX40L signaling pathway. The company conducts studies to assess safety, pharmacokinetics, pharmacodynamics, and efficacy in diseases such as atopic dermatitis and alopecia areata. IMG-007 is a monoclonal antibody engineered to silence antibody-dependent cellular cytotoxicity to improve tolerability while maintaining target engagement.

ImageneBio, Inc. operates in a competitive biopharmaceutical landscape marked by established biologics and emerging therapies targeting inflammatory pathways. Key competitors in atopic dermatitis include Sanofi/Regeneron's DUPIXENT, Leo Pharmaceuticals' ADBRY, Eli Lilly's EBGLYSS, and Galderma's NEMLUVIO, as well as JAK inhibitors such as Pfizer's CIBINQO, AbbVie's RINVOQ, and Eli Lilly's OLUMIANT. The company's competitive advantage lies in IMG-007's mechanism as a non-depleting OX40 antagonist with a long half-life, potentially enabling less frequent dosing and broader immune modulation beyond Th2-centric therapies.

ImageneBio, Inc. serves patients suffering from moderate-to-severe immunological and inflammatory diseases, particularly those unresponsive to or intolerant of existing topical or systemic therapies. The company's current focus is on adult patients with moderate-to-severe atopic dermatitis who have had inadequate response to topical treatments, with future potential to serve individuals with alopecia areata, asthma, rheumatoid arthritis, and related conditions.